Pharmaceutical Industry in
Zug

Strides Pharma International AG

Since 2012 · 11–20 empl.

The core activity of Fairmed Healthcare AG is the development, manufacture and distribution of generic and biosimilar medicines, in particular for infectious diseases, as well as the production of active ingredients and finished medicinal products. The company also offers solutions for pharmacies, including the development of its own pharmacy brands.

Guerbet Imaging Switzerland AG

Since 2013 · 1–10 empl.

Guerbet Imaging Switzerland AG is part of the Guerbet Group and provides solutions and services for medical imaging. Its activities focus on diagnostic and interventional imaging products, including contrast agents, injectors, accessories and consumables.

Almeda Pharmaceuticals AG

Since 2013 · 1–10 empl.

The core activity of Almeda Pharmaceuticals AG is the development, manufacture and marketing of pharmaceutical products, in particular specialized medicines, generics and dietary supplements. The company focuses on the areas of oncology, transplantation medicine, CNS diseases, antimicrobial therapies, rare diseases and nutrition supplements. Almeda Pharmaceuticals AG positions itself as a reliable partner for the distribution and marketing of medicines in the CIS region (Commonwealth of Independent States) and other selected geographical regions.

CRISPR Therapeutics AG

Since 2013 · 101–500 empl.

The core activity of CRISPR Therapeutics is the development of gene therapeutic medicines, particularly through the application of CRISPR-Cas9 technology, to cure diseases at the molecular level. The company focuses on developing medicines for various diseases such as sickle cell anemia, β-thalassemia, cancer, autoimmune disorders, and regenerative medicine.

Pfanstiehl GmbH

Since 2015 · 11–20 empl.

Pfanstiehl is a specialist in the manufacture of high-purity, endotoxin-free, metal-free injectable cGMP excipients and biopharmaceutical components for various applications in bioprocessing, formulation, and specialty research. The company also offers custom API manufacturing, custom ADC linker synthesis, and other services. The core activity of the company is the development and manufacture of high-quality excipients for the biopharma and pharmaceutical industries, particularly for the production of vaccines and medicines.

Vertex Pharmaceuticals (CH) GmbH

Since 2015 · 101–500 empl.

The core activity of Vertex Pharmaceuticals is the development and research of innovative therapies for severe and rare diseases, particularly through investments in science and the exploration of causal human biology at the molecular level.

Alnylam Switzerland GmbH

Since 2015 · 21–50 empl.

The company is a pharmaceutical or biotechnology company specializing in the development and manufacture of medicines for rare diseases. The core activity includes research and development of RNAi-based therapies, the manufacture and marketing of medicines, as well as the provision of patient services, including genetic counseling and patient advocacy.

Xantis Pharma AG

Since 2015 · 1–10 empl.

The core activity of Xantis Pharma AG is the development and provision of pharmaceuticals, with the aim of offering safe and affordable treatment options for all.

Elthera AG

Since 2016 · 11–20 empl.

The core activity of Elthera AG is the development of precision medicine oncology solutions, particularly the research and development of L1CAM-based immunotherapies to combat aggressive tumors.

Bioeq AG

Since 2016 · 11–20 empl.

The core activity of Bioeq AG is the development, manufacture and marketing of pharmaceutical products, particularly in the field of medicinal products. The company provides services such as quality control, regulatory affairs, supply chain management and logistics to support the manufacture and distribution of medicinal products.

Iovance Biotherapeutics GmbH

Since 2017 · 11–20 empl.

Iovance Biotherapeutics GmbH develops and investigates tumor‑infiltrating lymphocyte (TIL) therapies for the treatment of solid tumors. The company conducts preclinical and clinical research on T‑cell‑based immunotherapies, operates manufacturing capabilities and maintains a clinical pipeline and products shown on the website such as AMTAGVI (lifileucel) and Proleukin (aldesleukin).

Sarepta International Holdings GmbH

Since 2017 · 1–10 empl.

The core activity of Sarepta Therapeutics is the development and manufacturing of gene therapies for the treatment of rare diseases, particularly muscular dystrophies such as Duchenne muscular dystrophy, limb-girdle muscular dystrophy (LGMD), and Charcot-Marie-Tooth disease. The company focuses on researching and developing precision gene medicine and aims to increase efficiency in drug development and shorten the time from laboratory to patient.

Planarian Technologies AG

Since 2017 · 1–10 empl.

The core activity of Planarian Tech is the development and application of cellular technology for the treatment of dermatological diseases. The company researches and develops innovative solutions based on cell technology to help patients with skin diseases lead a healthier and more productive life.

Aphaia Pharma AG

Since 2018 · 21–50 empl.

The core activity of Aphaia Pharma AG is the development and marketing of pharmaceuticals, particularly in the fields of life sciences and biotechnology. The company focuses on the research and development of innovative therapeutics and medications, particularly in the areas of microvascular medicine and the treatment of diseases such as obesity and metabolic disorders.

Quercis Pharma AG

Since 2018 · 11–20 empl.

The core activity of Quercis Pharma AG is the development of pharmaceuticals, particularly the research and development of medications for the prevention of thrombosis and other diseases, such as cancer and neurological disorders. The company focuses on the development of Isoquercetin-based medications, such as Kinisoquin, and conducts clinical trials to test their efficacy and safety.

mybacs AG

Since 2018 · 11–20 empl.

The company mybacs develops and distributes products based on the latest scientific findings in the field of microbiome health, particularly probiotics and dietary supplements that aim to promote gut health and overall well-being.

Blueprint Medicines (Switzerland) GmbH

Since 2018 · 51–100 empl.

Blueprint Medicines is a pharmaceutical company specializing in the development and marketing of innovative medicines. The company's core activity is the research, development and marketing of precision medicines, particularly for the treatment of cancer and other serious diseases. The company focuses on developing medicines that target specific molecular mechanisms, enabling more effective and safer treatment of patients.

KD Swiss GmbH

Since 2018 · 1–10 empl.

KD Swiss GmbH is a CDMO for pharmaceutical and nutraceutical solutions. The company provides services and products in lipids, small molecules, APIs and intermediates, as well as finished dosage forms such as softgels and liquids.

Aurealis Therapeutics AG

Since 2018 · 21–50 empl.

The core activity of Aurealis Therapeutics is the development and marketing of bacteria-based cell and gene therapies for the treatment of chronic wounds and cancer. In particular, the company focuses on the development of proprietary technologies that use genetically modified Lactococcus cremoris bacteria to produce multiple human therapeutic proteins. The company's two leading clinical products are AUP-16 for chronic wounds and AUP-55 for cancer.

Mirum Pharmaceuticals AG

Since 2018 · 21–50 empl.

The core activity of Mirum Pharmaceuticals, Inc. is the development and marketing of medications, particularly for rare liver diseases. The company focuses on researching and developing therapies for patients with rare diseases and offers already approved medications such as LIVMARLI and CTEXLI.

IPSEN Pharma Schweiz GmbH

Since 2019 · 11–20 empl.

The core activity of Ipsen is the development and provision of innovative pharmaceutical products for people with rare or severe diseases, particularly in the therapeutic areas of oncology, neurology and rare diseases.

Insmed Switzerland GmbH

Since 2019 · 11–20 empl.

Insmed Corporation focuses on the development and commercialization of drugs for rare and serious diseases, particularly in the areas of respiratory diseases and rare diseases. The core activities include research and development of new drugs, the acquisition and licensing of clinical and commercial assets, the conduct of clinical trials, and the commercialization of drugs in the US, Europe, Japan, and other regions.

Deciphera Pharmaceuticals (Schweiz) AG

Since 2019 · 101–500 empl.

The core activity of Deciphera Pharmaceuticals, LLC is the development and manufacture of cancer treatments, particularly through the development of kinase inhibitors that target specific enzymes involved in the development and spread of cancer.

Pharvaris GmbH

Since 2020 · 11–20 empl.

Pharvaris GmbH is a late‑stage biopharmaceutical company developing novel oral bradykinin B2‑receptor antagonists. The company focuses on bradykinin‑mediated diseases, including hereditary angioedema (HAE) and acquired angioedema due to C1‑inhibitor deficiency, and is developing deucrictibant in immediate‑release and extended‑release formulations for on‑demand and prophylactic treatment.

Kiniksa Pharmaceuticals, GmbH

Since 2020 · 21–50 empl.

The core activity of Kiniksa Pharmaceuticals is the development and marketing of biopharmaceutical products, particularly therapeutics for unmet medical needs, with a focus on immunomodulation and cardiovascular diseases. The company concentrates on developing products that target unmet needs and neglected diseases and can offer life-changing treatments.

Swizzard Pharma AG

Since 2020 · 11–20 empl.

The core activity of Swizzard Pharma AG is to support companies in introducing medical products to the Swiss market. To this end, Swizzard offers a wide range of services, including market entry strategies, regulatory support, market access, product launch and distribution strategies. The company supports its customers in successfully introducing products to the Swiss market and helps them to turn their medical breakthroughs into innovative products that benefit patients in Switzerland.

MoonLake Immunotherapeutics AG

Since 2021 · 21–50 empl.

The core activity of MoonLake Immunotherapeutics AG is the development of innovative therapies for inflammatory diseases, particularly with the goal of improving the treatment of diseases such as psoriasis and hidradenitis suppurativa. The company focuses on the development of Sonelokimab, a Nanobody that specifically inhibits interleukins to reduce inflammation. The core activities include conducting clinical trials, developing new therapies, and licensing medications.

Atnahs Pharma Switzerland AG

Since 2021 · 101–500 empl.

The core activity of Pharmanovia is the development, manufacture, marketing and distribution of pharmaceuticals, particularly established branded medicines, as well as the rediscovery and repositioning of existing medicines. This also includes the acquisition and licensing of supportive therapies, the conduct of clinical trials and the management of approval procedures.

Essential Pharma Switzerland GmbH

Since 2021 · 21–50 empl.

The core activity of Essential Pharma is the acquisition, integration, optimization and maintenance of established, branded medicines, particularly those that are difficult to manufacture or treat rare diseases. The company focuses on the areas of Central Nervous System, Gastroenterology, Ophthalmology and rare diseases, and supplies patients in over 70 countries.

Neopharmed Gentili Schweiz GmbH

Since 2021 · 11–20 empl.

The core activity of BioCryst is the development and commercialization of medicines for rare diseases, particularly hereditary angioedema (HAE) and other rare disorders. The company focuses on the development of oral small molecules and protein therapeutics based on a combination of traditional biology, medicinal chemistry, and advanced technologies.

AVEA LIFE AG

Since 2021 · 11–20 empl.

Avea develops and manufactures dietary supplements based on scientific research and cutting-edge technology, with the goal of supporting human health and well-being.

Nektar Therapeutics Europe GmbH

Since 2021 · 1–10 empl.

Nektar Therapeutics Europe GmbH develops novel therapies for autoimmune and inflammatory diseases according to the information presented on the website. Its work focuses on immune modulation, including investigational medicines targeting regulatory T cells and other immunology pathways.

Jazz Pharmaceuticals Switzerland GmbH

Since 2021 · 1–10 empl.

Jazz Pharmaceuticals Switzerland GmbH is a biopharmaceutical company that develops and commercializes medicines. It focuses on treatments for patients with limited or no options, including therapies in rare disease, neuroscience (e.g., epilepsy) and oncology.

Orchard Therapeutics (Switzerland) GmbH

Since 2021 · 1–10 empl.

Orchard Therapeutics (Switzerland) GmbH develops gene therapies for rare inherited diseases. Its work focuses on ex vivo HSC gene therapy, in which a patient’s own blood stem cells are genetically modified outside the body and then reinfused.

ACROBiosystems AG

Since 2022 · 1–10 empl.

ACROBiosystems AG supplies life-science reagents and services, including recombinant proteins, antibodies, cell lines, cell culture reagents and assay kits. The company also provides GMP-grade materials, custom protein services and analytical/quality-control services to support cell and gene therapy development.

VIVUS (Switzerland) AG

Since 2022 · 101–500 empl.

The company's core activity is the development and marketing of pharmaceuticals, particularly for the treatment of severe medical conditions and life-threatening diseases. The company focuses on global development and marketing of medicines, including conducting clinical trials, regulating approval procedures, and marketing products in various regions, including North America and Europe.

Absci GmbH

Since 2022 · 11–20 empl.

Absci GmbH is a generative AI drug creation company. It develops biologic drug candidates through an integrated platform that combines data generation, AI model training, de novo design and wet-lab validation.

SpringWorks Therapeutics Europe GmbH

Since 2024 · 21–50 empl.

The company is a biotechnology company specializing in the development of drugs for the treatment of cancer, particularly rare cancer types such as Multiple Myeloma, Desmoid tumors and NF1-PN.